Diabetes - the Role of Metabolomics in the Discovery of New Mechanisms and Novel Biomarkers

Current Cardiovascular Risk Reports

Volumn 7, Issue 1, 2013, Pages 25-32

  Dunn, Warwick B ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Branched chain amino acids; Chromatography; Diabetes; Diabetic complications; Fatty acids; Insulin resistance; Intervention; Mass spectrometry; Metabolism; Metabolomics; Metabonomics; Nuclear magnetic resonance spectroscopy; Personalized medicine; cell, streptozotocin rat model; Treatment

Indexed keywords

ARACHIDONIC ACID; AROMATIC AMINO ACID; ASPARTIC ACID; BETAINE; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; CERAMIDE; CITRIC ACID; FATTY ACID; FRUCTOSE; GLUCOSE; GLUTAMIC ACID; GLYCEROPHOSPHOLIPID; GLYCINE; KYNURENIC ACID; LACTIC ACID; LEUCINE; LEUKOTRIENE; LYSINE; LYSOPHOSPHATIDYLCHOLINE; METHIONINE; PENTOSE PHOSPHATE; PHENYLALANINE; PIPECOLIC ACID; POLYOL; TRIACYLGLYCEROL; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG; VALINE;

AMINO ACID METABOLISM; DIABETES MELLITUS; GENOMICS; GLUCOGENESIS; GLYCOLYSIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; MODEL; NONHUMAN; PANCREAS ISLET BETA CELL; PULSE WAVE; REVIEW; RISK;

EID: 84872333711     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-012-0282-9     Document Type: Review

References (49)

1. World Health Organization. Burden: mortality, morbidity and risk factors. Available at http://www. who. int/diabetes/facts/en/index. html. Accessed September 2012.
2. World Health Organization. Facts and figures about diabetes. Available at http://www. who. int/mediacentre/factsheets/fs312/en/index. html. Accessed September 2012.
3. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 293-301.
4. van Gaal LF, De Block CE. Bariatric surgery to treat type 2 diabetes: what is the recent evidence? Curr Opin Endocrinol Diabetes Obes. 2012; 19: 352-8.
5. Friedrich N. Metabolomics in diabetes research. J Endocrinol. 2012. doi: 10. 1530/JOE-12-0120.
6. Dunn WB, Goodacre R, Neyses L, et al. Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis. 2011; 3: 2205-22.
7. Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2011; 40: 387-426.
8. Griffin JL, Vidal-Puig A. Current challenges in metabolomics for diabetes research: a vital functional genomic tool or just a ploy for gaining funding? Physiol Genome. 2008; 34: 1-5.
9. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008; 455: 1054-6.
10. •• Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011; 17: 448-53. This article shows for the first time how high quality experimental design and suitably sized subject cohorts coupled with discovery-based metabolomics can be applied to identify putative prognostic metabolic biomarkers of disease risk.
11. Felig P, Marliss E, Cahill Jr GF. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969; 281: 811-6.
12. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011; 121: 1402-11.
13. • Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012; 15: 606-14. This article highlights the synergistic roles and interplay of BCAA and fatty acids in insulin resistance.
14. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9: 311-26.
15. Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010; 3: 207-14.
16. Laferrere B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery vs dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011; 3: 80re2.
17. Mihalik SJ, Michaliszyn SF, de las Heras J, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012; 35: 605-11.
18. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr. 2011; 2: 445-56.
19. Macotela Y, Emanuelli B, Bang AM, et al. Dietary leucine-an environmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One. 2011; 6: e21187.
20. Collier JJ, Burke SJ, Eisenhauer ME, et al. Pancreatic beta-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One. 2011; 6: e22485.
21. Boslem E, MacIntosh G, Preston AM, et al. A lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. Biochem J. 2011; 435: 267-76.
22. Spegel P, Malmgren S, Sharoyko VV, et al. Metabolomic analyses reveal profound differences in glycolytic and tricarboxylic acid cycle metabolism in glucose-responsive and -unresponsive clonal beta-cell lines. Biochem J. 2011; 435: 277-84.
23. Pillai R, Huypens P, Huang M, et al. Aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor-1ß plays a critical role in maintaining glucose-stimulated anaplerosis and insulin release from pancreatic ß-cells. J Biol Chem. 2011; 286: 1014-24.
24. • Sysi-Aho M, Ermolov A, Gopalacharyulu PV, et al. Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol. 2011; 7: e1002257. This article describes a reverse translation approach to study the pathogenesis of autoimmune diabetes. The lipidomic patterns observed in nonobese prediabetic mice that progressed to develop autoimmune diabetes were similar to prediabetic children in the Type 1 Diabetes Prediction and Prevention project (DIPP) study.
25. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008; 205: 2975-84.
26. Dutta T, Chai HS, Ward LE, et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes. 2012; 61: 1004-16.
27. Ament Z, Masoodi M, Griffin JL. Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Med. 2012; 4: 32.
28. Galazis N, Iacovou C, Haoula Z, Atiomo W. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2012; 160: 121-30.
29. Makinen VP, Tynkkynen T, Soininen P, et al. Sphingomyelin is associated with kidney disease in type 1 diabetes (the FinnDiane study). Metabolomics. 2012; 8: 369-75.
30. Boini KM, Zhang C, Xia M, Poklis JL, Li PL. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther. 2010; 334: 839-46.
31. van der Kloet FM, Tempels FW, Ismail N, et al. Discovery of early-stage biomarkers for diabetic kidney disease using MS-based metabolomics (FinnDiane study). Metabolomics. 2012; 8: 109-19.
32. Ng DP, Salim A, Liu Y, et al. A metabolomic study of low estimated GFR in nonproteinuric type 2 diabetes mellitus. Diabetologia. 2012; 55: 499-508.
33. Zhu C, Liang QL, Hu P, Wang YM, Luo GA. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta. 2011; 85: 1711-20.
34. Ha CY, Kim JY, Paik JK, et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol. 2012; 76: 674-82.
35. Zhao T, Zhang H, Zhang X, et al. Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal. 2012; 60: 32-43.
36. Patterson AD, Bonzo JA, Li F, et al. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem. 2011; 286: 19511-22.
37. Brugnara L, Vinaixa M, Murillo S, et al. Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus. PLoS One. 2012; 7: e40600.
38. Nissim I, Horyn O, Daikhin Y, et al. Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics. Biochem J. 2012; 444: 537-51.
39. Fan TW, Lorkiewicz PK, Sellers K, et al. Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther. 2012; 133: 366-91.
40. Winder CL, Dunn WB, Goodacre R. TARDIS-based microbial metabolomics: time and relative differences in systems. Trends Microbiol. 2011; 19: 315-22.
41. Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem. 2012; 19: 2828-60.
42. Ugarte M, Brown M, Hollywood KA, et al. Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA). Genome Med. 2012; 4: 35.
43. McKillop AM, Flatt PR. Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care. 2011; 34: 2624-30.
44. Adamski J. Genome-wide association studies with metabolomics. Genome Med. 2012; 4: 34.
45. Bordbar A, Feist AM, Usaite-Black R, et al. A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol. 2011; 5: 180.
46. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012; 148: 1293-307.
47. Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011; 57: 231-40.
48. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther. 2011; 90: 52-66.
49. Langenberg C, Savage DB. An amino acid profile to predict diabetes? Nat Med. 2011; 17: 418-20.